AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

Highlights AIM’s Significant Momentum and Ongoing Achievement of Clinical and Regulatory Milestones


Urges Shareholders to Protect AIM’s Progress by Voting for the Company’s Board of Directors...

Related Keywords

Delaware ,United States ,Netherlands ,Nebraska ,American ,Thomask Equels ,Michaelj Xirinachs ,Franzn Tudor ,Astrazeneca Imfinzi ,Williamm Mitchell ,Robertl Chioini ,Nancyk Bryan ,Stewartl Appelrouth ,Tedd Kellner ,Early Access Program ,American Journal Of Cancer Research ,Company On Twitter ,Group Is Not ,Indevus Pharmaceuticals ,University Of Nebraska ,Company Definitive Proxy Statement ,Linkedin ,Delaware Court ,Erasmus Medical Center ,Immunotech Inc ,Glaxosmithkline ,Board Audit Committee ,Company Bylaws The ,Astrazeneca ,Bayer Pharmaceuticals ,Company Board Of Directors ,Facebook ,Company Phase ,Exchange Commission ,Definitive Proxy Statement ,Tech Inc ,Fellow Shareholders ,Activist Group ,Rockwell Medical ,Substantial Momentum ,Bring New Therapies ,Roswell Park Comprehensive Cancer ,American Journal ,Cancer Research ,Refreshed Board Has ,Right Industry Experience ,Successfully Lead ,Executive Vice Chairman ,Chief Executive Officer ,Vanderbilt University School ,Chronix Biomedical ,Not Acting ,Best Interests ,Trusted With Your ,Tech Board ,Private Securities Litigation Reform Act ,Initial Statements ,Beneficial Ownership ,Markets ,